In vivo activity of mutacin B-Ny266.
OBJECTIVE
The objective of this study was to assess the in vivo activity of mutacin B-Ny266 (a bacteriocin produced by Streptococcus mutans) in order to eventually use it as an antibiotic.


METHODS
Intraperitoneal infection was induced with a methicillin-susceptible Staphylococcus aureus strain in mice. Some of the mice were simultaneously injected intraperitoneally with mutacin B-Ny266, some with the vehicle only and some with vancomycin.


RESULTS
While there was 70 and 100% mortality in the control groups of mice, no mortality was observed in the mice injected with vancomycin or mutacin B-Ny266.


CONCLUSIONS
The results presented here show, for the first time, the in vivo efficacy of a mutacin (B-Ny266) against an experimental intraperitoneal infection by S. aureus in a mouse model.
Mota-Meira
Marilaine
M
Department of Biological and Chemical Sciences, Faculty of Pure and Applied Sciences, The University of the West Indies, Cave Hill Campus, PO Box 64, Bridgetown, Barbados.
Morency
Helene
H
Lavoie
Marc C
MC
D000818:Animals; D001430:Bacteriocins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D051379:Mice; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000008:administration & dosage / Q000494:pharmacology
D001430:Bacteriocins; C107503:mutacin B-Ny266; D014640:Vancomycin